This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Use of Lapis Judaicus to Dissolve Kidney Stones

This study has been completed.
Information provided by (Responsible Party):
Pouya Faridi, Shiraz University of Medical Sciences Identifier:
First received: September 25, 2011
Last updated: November 29, 2013
Last verified: November 2013

The investigators will investigate the safety and effectiveness of an Iranian traditional medicine regarding its ability to dissolve existing kidney stones. Calcium stone formers will be recruited for a 12 week trial. Each subject will receive Lapis judaicus or placebo in random order. End points are changes in urinary chemistries and stone burden by Ultra sonography / CT scan.

It will be used in proven calcium stone forming adults who are not pregnant. This phase is a double blind, randomized, placebo controlled Entry, first and 12 week 24 hour urine supersaturations, pH and sodium determinations will be collected. Entry and final stone quantification Ultra sonography / CT scan will be performed. End points will be changes in urine chemistry/supersaturation and stone quantitative stone volume.

Condition Intervention Phase
Kidney Calculi Drug: Lapis Judaicus Drug: Placebo Phase 1 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Pouya Faridi, Shiraz University of Medical Sciences:

Primary Outcome Measures:
  • Stone size after 12 weeks [ Time Frame: 8 weeks and 12 weeks ]
    24 hour urine chemistries 24 hour urine supersaturation Stone quantification CT

Enrollment: 60
Study Start Date: January 2011
Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo Drug: Placebo
2 g capsule per day.
Active Comparator: Lapis judaicus Drug: Lapis Judaicus
2 g capsule per day.


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age 18 or over
  • Mentally competent
  • Medically effective birth control if fertile female
  • History of calcium containing stone AND current quantifiable stone
  • Able to comply with protocol

Exclusion Criteria:

  • Prisoner
  • Pregnant
  • CKD
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01443702

Iran, Islamic Republic of
Motahhari Medical Center
Shiraz, Fars, Iran, Islamic Republic of
Sponsors and Collaborators
Shiraz University of Medical Sciences
Study Chair: Jamshid Roozbeh, MD Shiraz University of Medical Sciences
  More Information

Responsible Party: Pouya Faridi, Principal Investigator, Shiraz University of Medical Sciences Identifier: NCT01443702     History of Changes
Other Study ID Numbers: Shirazums CT-90-5677
Study First Received: September 25, 2011
Last Updated: November 29, 2013

Keywords provided by Pouya Faridi, Shiraz University of Medical Sciences:
Kidney Calculi
Iranian traditional medicine
Lapis judaicus

Additional relevant MeSH terms:
Kidney Calculi
Pathological Conditions, Anatomical
Kidney Diseases
Urologic Diseases
Urinary Calculi processed this record on September 20, 2017